IsoRay seeks polymer seed deal with International Brachytherapy
This article was originally published in Clinica
Executive Summary
In what promises to drive down manufacturing costs for its Cs-131 brachytherapy isotope and improve its clinical performance, IsoRay plans to license from International Brachytherapy (IBt) polymer seed technology for use with its product in brachytherapy. IsoRay, together with its IsoRay Medical subsidiary and IBt have signed a letter of intent for a technology licensing agreement covering North America.